March 2, 2021 | Daily JAM, INCY, Jubak Picks, Volatility |
Shares of biotech stock Incyte (INCY) have been down significantly in 2021. For the year to date, as of the close on March 2, the shares were down 8.45%. In the last month they’ve tumbled 12.42%. So what’s wrong? Pretty much nothing. With the individual stock anyway. What we’re watching is a lot of selling in the biotech sector as part of the recent sell-off on risk. And on substantial profit taking.
August 4, 2020 | Daily JAM, INCY, Jubak Picks, Stock Alerts |
Shares of biotech Incyte (INCY) were down 2.60% as of 1:30 p.m. Tuesday on earnings and revenue that stomped Wall Street projections. The company reported second quarter adjusted earnings of $1.24 a share versus Wall Street projections for 50 cents a share. Earnings...
June 22, 2020 | Daily JAM, INCY, Jubak Picks, Stock Alerts |
I admit it. I feel silly talking about price targets and valuations in this market. After all everything is just going to the sky. Infinity and Beyond!!! But, as silly as I may feel, I don't think the gods of investing have repealed the laws of valuation. At some...
May 24, 2019 | Daily JAM, INCY, Stock Alerts |
Jubak Picks and Volatility Portfolio member Incyte (INCY) closed up 1.55% today to $81.75 on news that the U.S. Food and Drug Administration had approved the company's Jakafi for treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the...
April 10, 2019 | Daily JAM, INCY, Volatility, You Might Have Missed |
There's a good chance that Incyte (INCY) will miss Wall Street earnings and revenue projections when it reports first quarter results on April 30. That's because Incyte is a biotech adolescent. Think awkward. The company is old enough to have substantial revenue from...
January 24, 2019 | Daily JAM, INCY, Stock Alerts, Volatility |
The Biotech sector is a prototypical risk on/risk off asset class. Just look at the performance of Incyte if you'd like an example. The stock plunged to a low of $58.58 on December 24as investors and traders shunned risk--risk of a recession, risk of the U.S.-China...
January 8, 2019 | Daily JAM, INCY, IONS, NKTR |
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday's close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big drug...
December 3, 2018 | Daily JAM, INCY, Stock Alerts |
Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte's (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte's Jakafi in combination with...
October 19, 2018 | Daily JAM, INCY, Stock Alerts |
Shares of Incyte  (INCY) climbed 2.51% today on the announcement of positive results from a Phase 2 clinical trial, GEOMETRY mono-1, evaluating MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer. The company presented the data at...
August 28, 2018 | Daily JAM, INCY |
Shares of Incyte (INCY), a member of my Jubak Picks portfolio, have been marching steadily higher in the last couple of weeks. The stock is 19.6% higher since the $61.75 low on August 6. And it's up another 2.06% today, Tuesday, August 28. But the call options I own...
August 24, 2018 | Daily JAM, INCY, Stock Alerts, Volatility |
I am on vacation until August 26. I am using that downtime to catch up on some of the earnings reports I missed during the very busy second quarter earnings season. On July 30 Incyte (INCY) reported second quarter earnings of 26 cents a share, 4 cents below the Wall...
June 1, 2018 | Daily JAM, INCY, Stock Alerts |
Today the U.S. Food & Drug Administration did finally approve Baricitinib, now known as Olumiant, for the treatment of moderately-to-severely active rheumatoid arthritis. But the approval carries more restrictions than expected. The FDA approved only the 2...
